You can now review and comment on this draft scope.

NICE guidance and quality standards that may be affected by this guideline update

NICE technology appraisals

NICE technology appraisal guidance will be included where relevant. For further details, see our web page on bringing our guidance together by topic.

NICE is currently consulting on a multiple technology appraisal of resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis. See the in development page for more details about its suggested remit, draft scope and provisional stakeholder list of consultees and commentators.

The draft scope consultation closes on metabolic dysfunction-associated steatotic liver disease: assessment and management on 01 June 2025 at 11:59pm.

How to comment

  1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response, and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

  1. Read the consultation documents

Documents to comment on:

  1. Add your comments
  • You must use this comments form.
  • You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

  • The areas that will have the biggest impact on practice and be challenging to implement
  • How to help users overcome challenges

Developing NICE guidelines: how to get involved suggests some other areas to comment on.

  1. Email the form to us

Email: [email protected]

Deadline: 01/06/2025, 11:59pm 

Documents